>> Continued From the Previous Page <<
“And now she has gone full Demi Moore – in her seventies with the tight braid and the super tight outfit. I don’t like it,” Kelly added, reflecting the unease many feel about celebrity transformations in their later years.
What mainstream outlets aren’t reporting is more shocking than Oprah’s Paris look. She joined WeightWatchers’ board in 2015, invested $43.2 million, and became the living embodiment of their program. The stock nearly doubled, and Oprah’s image became synonymous with health and willpower. For nearly a decade, she convinced Americans that following her program could beat obesity.
Then in 2023, while still on the board, she quietly began taking GLP-1 medication—a class of drugs including semaglutide, often marketed as Ozempic. She never announced it publicly. By February 2024, she stepped down from the board. The stock collapsed immediately, hitting its lowest point since 2001. By May 2025, the company she championed filed for Chapter 11 bankruptcy, buried under more than a billion dollars of debt.
The millions who followed her WeightWatchers plan were left paying monthly fees and counting points, all while the company crumbled and Oprah headed to Paris. Now, with her new book Enough, co-written with an obesity specialist, she admits her past advice was wrong. “I came to understand that overeating doesn’t cause obesity. Obesity causes overeating,” she told People magazine.
Kelly and her guest Mark Halperin also spoke about the broader implications of these drugs. “It is just these fallen faces,” Halperin said, commenting on the celebrity trend of rapid weight loss. Dermatologist Dr. Paul Jarrod Frank, who coined the term “Ozempic Face,” has warned that fast fat loss in older adults can leave the face hollow and sagging, with skin that doesn’t bounce back. Sharon Osbourne has admitted she went “too far” and that even fillers can’t repair the damage.
Halperin was blunt: “It is not proven that this is a healthy way to live.” The reality is that nobody knows what decades on semaglutide will do, especially for someone in their seventies. These medications have been mainstream for barely three years, and pharmaceutical companies charging $1,000 to $1,500 per month aren’t studying long-term effects.
Oprah calls this “a lifetime thing,” backed by trainers, doctors, and resources most Americans could never afford. A 2025 KFF poll found 18 percent of American adults had tried a GLP-1—but most are self-administering expensive drugs without oversight, hoping for the best.
Megyn Kelly’s observations resonate: celebrating this transformation ignores the hidden costs—both financial and physical. And while Oprah found a way out, the rest of America may not be so lucky. As Kelly concluded, the woman at Paris Fashion Week barely resembled the Oprah who spent a decade promising empathy, understanding, and guidance to those struggling with their weight.
